There is a particular kind of tragedy that attends a preventable death. Not the sudden grief of an unforeseeable accident or the hard acceptance of a disease science has not yet learned to treat, but the specific, grinding anguish of watching something happen that you know how to stop.
Nigeria is living inside that tragedy in 2026 at a scale that the numbers, as large as they are, struggle to fully communicate.
Nigeria accounts for the highest percentage of the global malaria burden compared to any other country, with 24.3 percent of global estimated malaria cases and 30.3 percent of estimated deaths in 2024, as well as an estimated 54.6 percent of malaria cases in West Africa.
Nearly one in three malaria deaths on earth happens in Nigeria. Not in a country without resources, without educated health professionals, or without awareness of the problem. In Nigeria, a country that has been conducting malaria awareness campaigns, distributing insecticide-treated bed nets, administering antimalarial drugs, and holding high-level malaria summits for more than three decades. A country whose health minister estimated the annual economic burden of the disease at between 1.1 and 1.6 billion dollars. A country that, according to its own National Malaria Strategic Plan, was supposed to have achieved a parasite prevalence below ten percent by 2025.
That target was not met. Not even close. And the reasons why it was not met are a precise and damning map of the failures of Nigerian public health governance that extends far beyond malaria into every aspect of the country's relationship with preventable suffering.
The Numbers That Should Be Unacceptable
Before the analysis, the scale needs to be established plainly.
Globally, there were an estimated 282 million malaria cases and 610,000 deaths in 2024, roughly nine million more cases than the previous year. The WHO African Region was home to about 95 percent of all malaria cases and deaths. Children under five years of age accounted for about 76 percent of all malaria deaths in the region. Over half of all deaths in the region occurred in three countries: Nigeria at 31.9 percent, the Democratic Republic of the Congo at 11.7 percent, and Niger at 6.1 percent.
Malaria is transmitted throughout Nigeria, with 97 percent of the population at risk of being infected. This is not a regional or localised crisis. It is a nationwide condition of permanent vulnerability affecting essentially every Nigerian.
Five countries, including Nigeria, Democratic Republic of Congo, Ethiopia, Mozambique, and Uganda, contribute more than half of all global cases. According to the 2025 Goalkeepers report, in 2024, 4.6 million children died before their fifth birthday. In 2025, that number is projected to rise for the first time this century, by over 200,000, to an estimated 4.8 million children.
The trajectory is going in the wrong direction. Not holding steady. Not improving slowly. Moving in the wrong direction, with case counts rising and the tools that were supposed to bend the curve facing new and intensifying threats.
Nigeria's Coordinating Minister of Health and Social Welfare, Prof. Muhammad Ali Pate, has estimated the economic burden of malaria at between 1.1 billion and 1.6 billion dollars annually in healthcare costs and lost productivity, warning that the figure could rise to 2.8 billion dollars by 2030. That projection is not a worst-case scenario. It is the forecast if current trends persist, which they show every sign of doing.
Why Nigeria Bears This Burden: The Structural Conditions
Understanding why Nigeria accounts for nearly a third of the world's malaria deaths despite decades of intervention requires understanding the specific structural conditions that make Nigeria uniquely vulnerable and uniquely resistant to control efforts simultaneously.
The first and most fundamental factor is scale. Nigeria's large population, along with other factors such as sanitation management and vegetation, favours mosquito breeding, which accounts for the persistent rise in malaria transmission. With over 220 million people, most of them in high-transmission zones, even a moderate national prevalence rate translates into an enormous absolute number of cases and deaths. Nigeria cannot be compared to smaller African nations in terms of the feasibility of achieving the coverage levels that malaria elimination requires.
The ecological conditions that make Nigeria particularly hospitable to malaria transmission are not incidental. Warm temperatures, seasonal but heavy rainfall, dense vegetation across the southern zones, and the extensive river systems and waterlogging that characterise much of the country's geography create ideal breeding conditions for the Anopheles mosquito. These conditions exist year-round rather than seasonally in many parts of the country, meaning there is no natural respite during which transmission breaks and the parasite burden in the population reduces.
Nigeria's diverse mosquito population adds another layer of complexity. Vectors differ not only across regions but sometimes within the same community, responding differently to control measures. Recent surveillance confirmed the presence of Anopheles stephensi, an invasive mosquito species from Southeast Asia that thrives in urban environments and resists multiple insecticides, raising new challenges for malaria control.
The arrival of Anopheles stephensi in Nigeria is a development that deserves serious public health attention that it has not yet fully received. The traditional Anopheles gambiae complex that has driven Nigeria's malaria burden is primarily a rural species that breeds in outdoor water bodies. Stephensi is an urban species that breeds in water storage containers, flowerpots, roof gutters, and the various small water-holding structures that characterise Nigerian urban environments. Its resistance to multiple insecticides means that the standard vector control tools, indoor residual spraying and insecticide-treated nets, are less effective against it. As Nigeria urbanises rapidly, the introduction of an urban-adapted, insecticide-resistant malaria vector into the country's major cities is a potential escalation of the crisis that current control strategies were not designed to address.
The Double Resistance That Is Undermining Every Tool We Have
The single most technically alarming development in Nigeria's malaria situation is not the scale of the burden, which has been present for decades, but the emergence of resistance to the tools that have historically been most effective at reducing that burden.
A major stumbling block to the elimination of malaria is the issue of drug resistance. Eight countries reported confirmed or suspected antimalarial drug resistance, including to artemisinin. The report estimated a potential 16 million more annual cases and 80,000 additional deaths if resistance continues to spread. Rising insecticide resistance compounds this threat, weakening some of the most important tools used to control malaria.
Artemisinin-based combination therapies are the backbone of malaria treatment in Nigeria. They replaced chloroquine and sulfadoxine-pyrimethamine, both of which became ineffective as the malaria parasite developed resistance to them over the decades when they were the standard of care. The artemisinin-based therapies that replaced them were, for many years, reliably effective in Nigeria. That reliability is now being tested by the emergence of partial resistance.
Dr. Adeola Olukosi, Director of Research and Head of NIMR's Malaria Research Group, placed resistance at the heart of malaria's persistence. Drug resistance by parasites and insecticide resistance by mosquitoes have been with us for a very long time. We have a limited arsenal, and the pressure we apply will always drive resistance.
Olukosi warned against continued use of banned drugs like chloroquine, adding that individual success with such medicines sustains resistant parasite populations and undermines public health gains.
The insecticide resistance dimension is equally serious. Despite spending more than one billion dollars every year on drugs, insecticide-treated nets, diagnostics, and public health campaigns, malaria remains deeply entrenched in Nigeria, a paradox experts at the Nigerian Institute of Medical Research attribute not to failed science but to biological resistance, environmental conditions, human behaviour, and weak implementation gaps.
Mosquitoes in many parts of Nigeria have developed resistance to the pyrethroid insecticides used in the standard treated nets that have been the primary vector control tool for the past fifteen years. When mosquitoes have developed resistance to the insecticide coating a bed net, the net still provides a physical barrier but loses the killing effect that has historically been responsible for the largest reduction in transmission. The World Health Organisation has developed next-generation nets that combine pyrethroids with a second insecticide from a different class, providing a means of overcoming single-insecticide resistance. These nets have shown dramatically superior efficacy in trials and in early deployments. But their cost is higher and their rollout in Nigeria has been far slower than the resistance problem demands.
The Funding Gap That Is Widening At the Worst Possible Time
Global malaria funding in 2024 was 3.9 billion dollars, only 42 percent of the 9.3 billion dollar target for 2025. Overseas Development Aid from wealthy countries has fallen by around 21 percent. Without more investment, there is a risk of a massive, uncontrolled resurgence of the disease.
This funding shortfall has direct and measurable consequences in Nigeria. The Global Fund to Fight AIDS, Tuberculosis and Malaria has historically been the largest external funder of Nigeria's malaria control programme, supporting procurement of nets, drugs, diagnostics, and the operational capacity of the National Malaria Elimination Programme. Reductions in Global Fund allocations or disbursements translate immediately into gaps in net distribution campaigns, disruptions to drug supply chains, and reduction in the community health worker capacity that delivers interventions to the most remote and most vulnerable populations.
Malaria research in Nigeria still relies heavily on external grants, though political commitment is improving. This dependency is both a vulnerability and a governance failure. A country that accounts for nearly a third of the world's malaria deaths should not be primarily dependent on external funding to address its most significant disease burden. The domestic budget for malaria control, while improving, remains inadequate relative to the scale of the challenge and the magnitude of the economic cost that malaria imposes on the Nigerian economy.
The fiscal logic of investing more in malaria control is actually compelling even in narrow economic terms. If the disease costs the economy between 1.1 and 1.6 billion dollars annually, and if investment of a fraction of that in more effective control could meaningfully reduce that burden, the return on investment from domestic funding of malaria control is extraordinarily high compared to most other public health expenditures. The Ministry of Finance's engagement with this argument, rather than treating malaria as purely a health ministry concern, is one of the key shifts that advocates for increased domestic funding are pursuing.
Climate Change: The Variable That Makes Everything Harder
Total malaria deaths increased, with 610,000 deaths in 2024 compared to 598,000 deaths reported in 2023. Part of this increase reflects climate dynamics that are expanding the geographic range and extending the seasonal duration of malaria transmission across Nigeria.
Changing rainfall patterns driven by climate change are creating new transmission dynamics. Seasonal flooding, increasingly severe across states like Kogi, Benue, and the Northeast, creates temporary breeding sites for mosquitoes across large areas that were previously less affected. The flooding itself is becoming more predictable in its seasonality, which means transmission peaks are intensifying in the flood-affected periods even if the overall pattern of transmission remains similar.
Rising temperatures are extending the zones and the seasons within which malaria transmission is viable. Mosquitoes require temperatures above approximately eighteen degrees Celsius for development, and the malaria parasite requires warmth for the incubation period within the mosquito. As average temperatures rise, areas at higher elevations and in more northern parts of Nigeria that previously had limited or seasonal transmission are experiencing year-round infection risk for the first time.
The convergence of these climate trends with the resistance dynamics and the funding shortfalls means that the environment for malaria control is becoming more challenging at precisely the moment when the tools available are becoming less effective and the resources available are insufficient.
The Children and the Mothers
Behind every percentage in the burden statistics is a specific human being. The WHO and UNICEF data on malaria in children under five and in pregnant women in Nigeria are not abstract public health metrics. They describe what happens inside millions of Nigerian families every year.
In Africa, 75 percent of malaria deaths are in children under five years old. In Nigeria specifically, malaria is a leading cause of death among children under five, with an estimated 95,000 annual child deaths. A child who survives a severe malaria episode involving cerebral involvement faces risks of lasting neurological damage that affects cognitive development, educational attainment, and lifetime economic potential, long after the acute illness has resolved. The damage from malaria to Nigeria's human capital extends far beyond the mortality statistics.
For pregnant women, malaria poses specific and severe risks. Malaria infection during pregnancy causes placental malaria, which impairs fetal growth and increases the risk of low birth weight, a major predictor of infant mortality and developmental problems. Nigeria's target of ensuring that 63 percent of pregnant women receive three or more doses of sulfadoxine-pyrimethamine, the preventive therapy recommended for this population, has been substantially missed. The proportion of pregnant women who received at least three doses of sulfadoxine-pyrimethamine between 2018 and 2021 increased from 16.6 percent to 31 percent. Despite the increase, it still means that only one in every three pregnant women is adequately protected against malaria during her pregnancy.
One in three. In 2026. With a preventive medicine that costs a fraction of a dollar per dose. The gap between what is achievable and what is being achieved is not primarily a gap of knowledge or technology. It is a gap of delivery, which is a gap of political priority and governance capacity.
What Is Actually Being Done: The Programmes and Their Limits
Nigeria is not passive in the face of its malaria burden. The National Malaria Elimination Programme operates a significant portfolio of interventions, supported by the Global Fund, the US President's Malaria Initiative, UNICEF, WHO, and domestic government funding. The Government of Nigeria has secured credits from three multilateral banks totalling 364 million dollars to fund health sector interventions in thirteen states for five years, with malaria a priority area.
An average 54 million children received Seasonal Malaria Chemoprevention across nineteen countries in 2024, an MMV-supported intervention that has proven highly effective in reducing malaria cases and deaths in high-transmission areas. Nigeria participates in the SMC programme in its Sahelian northern states, where the seasonal transmission pattern makes the monthly dosing approach feasible and effective.
The malaria vaccine rollout represents the most significant new tool available in the fight against Nigerian malaria. By the end of 2024, malaria vaccines had been introduced in seventeen countries, with over 10.5 million doses delivered, protecting at least 2.1 million children. Nigeria's integration of the RTS,S and R21 malaria vaccines into its routine immunisation programme, if achieved at the scale required, could significantly reduce child mortality from malaria in the years ahead. But vaccine coverage depends on the same primary healthcare infrastructure whose inadequacy underlies every other delivery failure in Nigerian health.
One emerging strategy reshaping malaria control is artificial intelligence. During a large-scale campaign in Kaduna State, AI tools guided evidence-driven interventions, tracked implementation in real time, and identified gaps instantly. The use of AI and data analytics to optimise malaria intervention delivery, by identifying geographic areas of high transmission that are not receiving adequate coverage and by monitoring supply chain failures before they create distribution gaps, represents a promising adaptation of modern technology to the challenge of implementation at scale.
The Way Forward: What Genuine Progress Requires
The convergence of resistance, funding gaps and climate impacts means we cannot afford complacency, said Malaria Consortium's Chief Executive, James Tibenderana. We have the evidence, tools and the knowledge to protect millions of lives.
The technical pathway to meaningful reduction in Nigeria's malaria burden is not mysterious. It has been articulated clearly in the WHO's World Malaria Report, in NMEP's strategic plans, in academic literature, and in the recommendations of every major review of the Nigerian malaria programme. The pathway requires the following:
Accelerated rollout of next-generation tools. The dual-insecticide nets that overcome pyrethroid resistance have demonstrated superior efficacy in settings comparable to Nigeria. Their cost is higher than standard nets but the cost-effectiveness calculation, in terms of lives saved per dollar spent, is strongly positive given the resistance levels in Nigerian mosquito populations. The malaria vaccines, particularly R21, need to reach the scale of coverage achieved by routine childhood vaccines rather than the pilot-programme coverage that currently defines their reach. A novel malaria treatment, ganaplacide-lumefantrine, achieved positive Phase 3 results and is expected to be submitted to regulatory authorities in 2026. As the first non-artemisinin-based drug in 25 years, it also has the potential to kill drug-resistant parasites and block transmission. Nigeria's regulatory and procurement systems need to be ready to adopt this drug quickly once it receives regulatory approval, rather than experiencing the multi-year delays that have historically slowed the uptake of new malaria tools.
Stronger primary healthcare delivery systems. Every malaria intervention in Nigeria, whether drugs, nets, vaccines, or rapid diagnostic tests, depends on delivery through primary healthcare facilities and community health workers. The chronic underfunding and underfunctioning of the primary healthcare system is the single most important bottleneck in Nigerian malaria control. Without adequate staffing, consistent drug and diagnostic supply, reliable cold chain for vaccines, and community health worker capacity, no combination of technical innovations will produce the coverage required.
Domestic financing commitment that matches the scale of the problem. Malaria research in Nigeria still relies heavily on external grants. Olukosi stressed the need for stronger domestic ownership, not only of programmes, but of research priorities and tool development. We cannot outsource our health security. A Nigeria that is spending more than a billion dollars annually on generator fuel to compensate for electricity that the government has not delivered can also make the decision to spend more than a billion dollars annually on malaria control that would protect its citizens from the country's greatest infectious disease killer.
Overdiagnosis and rational treatment. Obafunwa noted that malaria is often overdiagnosed, masking other illnesses and weakening trust in interventions, adding that for years, every fever was called malaria. If you do not test properly, you treat wrongly and the real disease progresses. The expansion of rapid diagnostic testing to ensure that every suspected malaria case is confirmed before treatment is both a clinical and a public health priority, both because it ensures that patients with other illnesses receive appropriate care and because it reduces the antibiotic pressure on the malaria parasite that drives resistance.
Behavioural change that reaches the most vulnerable. Insecticide-treated bed nets only protect people who sleep under them. Antimalarial drugs only help people who seek treatment promptly at qualified facilities. Preventive medications only work for pregnant women who attend antenatal care regularly. The gap between tool availability and tool utilisation is a behavioural and social gap that requires culturally appropriate, community-driven communication strategies rather than top-down public health messaging that does not reach the populations most at risk.
A Question of Urgency
Nigeria set a target in its 2021 to 2025 National Malaria Strategic Plan to reduce malaria deaths to below fifty per thousand live births by 2025 and to achieve parasite prevalence below ten percent. Nigeria did not make the WHO's list of nations that had successfully reduced malaria incidence and fatalities by the end of 2020. The 2025 targets also went unmet.
The next strategic cycle, targeting malaria eradication by 2030, has a five-year window. That window will close faster than it appears. The new drug resistance threats that have arrived in the past two years, the climate-driven expansion of transmission zones, the arrival of a new urban-adapted mosquito vector, and the funding environment that is shrinking rather than expanding: all of these create conditions in which the 2030 target is not merely ambitious but genuinely at risk of becoming unreachable if the current trajectory is not changed urgently and substantially.
WHO Director-General Dr. Tedros Adhanom Ghebreyesus warned that increasing numbers of cases and deaths, the growing threat of drug resistance and the impact of funding cuts all threaten to roll back the progress we have made over the past two decades.
In Nigeria's specific context, rolling back progress is not an abstract risk. It is the current direction of travel. The case counts are rising. The resistance threats are intensifying. The funding is insufficient. The primary healthcare delivery capacity remains inadequate. And approximately ninety-five thousand Nigerian children under the age of five are dying from malaria every year, most of them in circumstances where the tools that could have saved them exist and are available, but were not deployed effectively enough to reach them in time.
The question for Nigeria's political leadership, its health system administrators, its civil society, and its citizens is not whether the tools to reduce this toll exist. They do. It is not whether Nigeria can afford to invest more in addressing its greatest infectious disease burden. It can, and the economic returns from doing so are substantial. The question is whether there is sufficient urgency, sufficient accountability, and sufficient political will to treat a problem that kills nearly a third of the world's malaria victims as the national emergency it actually is, rather than as a background health challenge that can be managed at insufficient scale indefinitely while the country focuses on other priorities.
Malaria is a solvable problem. Nigeria is the country where the most lives are at stake. The only variable that is genuinely uncertain is whether Nigeria will choose to solve it.
Important Note: This article is for informational and educational purposes. If you or a family member has symptoms of malaria, including fever, chills, headache, or fatigue, please seek medical attention promptly from a qualified healthcare provider. Do not self-medicate with unverified treatments.